REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study

Figure 2

ICI-2 progression-free survival according to ICI-1 PFS. PFS, progression-free survival; CI, confidence interval; NR, not reached; mo, months.